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Abstract
 
In vivo priming of antigen-specific CD8
 
 
 
 T cells results in their expansion and differentiation
into effector T cells followed by contraction into a memory T cell population that can be
maintained for life. Recent evidence suggests that after initial antigenic stimulation, the magni-
tude and kinetics of the CD8
 
 
 
 T cell response are programmed. However, it is unclear to what
extent CD8
 
 
 
 T cell instruction in vivo is modulated by costimulatory signals. Here, we dem-
onstrate that constitutive ligation of the tumor necrosis factor receptor family member CD27
by its ligand CD70 quantitatively augments CD8
 
 
 
 T cell responses to influenza virus infection
and EL-4 tumor challenge in vivo by incrementing initial expansion and maintaining higher
numbers of antigen-specific T cells in the memory phase. Concomitantly, the quality of anti-
gen-specific T cells improved as evidenced by increased interferon (IFN)-
 
 
 
 production and a
greater cytotoxic potential on a per cell basis. As an apparent consequence, the superior effector
T cell formation induced by CD70 protected against a lethal dose of poorly immunogenic EL4
tumor cells in a CD8
 
 
 
 T cell– and IFN-
 
 
 
–dependent manner. Thus, CD70 costimulation
enhances both the expansion and per cell activity of antigen-specific CD8
 
 
 
 T cells.
Key words: costimulation • inﬂuenza virus • tumor immunity • MHC tetramer • 
TNF family member
 
Introduction
 
In response to viruses, intracellular bacteria, and a wide
range of tumors, antigen-specific CD8
 
 
 
 T cells have to ex-
pand for host defense (1, 2). Characteristically, an antigen-
specific CD8
 
 
 
 T cell response consists of three phases. In
the expansion phase, antigen-specific T cells rapidly increase
in numbers by cell divisions, and effector functions are
acquired. After viral clearance, 
 
 
 
90% of the effector T
cells are eliminated by apoptosis. This contraction phase
gradually converts into the maintenance phase, in which
the surviving antigen-specific T cells form the long-lived
memory CD8
 
 
 
 T cell population (3, 4).
After initiation, the transition through these stages of
CD8
 
 
 
 T cell development is directed by an instructional
program that commits CD8
 
 
 
 T cells to proceed with their
differentiation (5–8). The duration of antigenic stimulation
appears to determine whether clonal expansion is abortive
or extensive (9). The fine-tuning mechanisms on the phases
and quality of this program have been poorly investigated.
Thus far, it has been shown that the cytokine IL-2 delays
the contraction phase (10), whereas the opposite has been
found for IFN-
 
 
 
 (11). Although it can be assumed that signals
transmitted via costimulatory receptors also influence this
instructional program, for many costimulatory interactions,
the nature of these changes has not been established.
The TNF receptor family member CD27 is constitu-
tively expressed on the majority of T cells and on subsets of
antigen-experienced B cells, NK cells, and hematopoietic
progenitor cells (12–15). In contrast, expression of its
ligand CD70 is tightly regulated and only transiently found
on activated lymphocytes and dendritic cells (16–18). In
vitro studies showed that CD27–CD70 interactions are in-
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volved in T cell expansion (12, 19, 20) and in the enhance-
ment of differentiation of CD8
 
 
 
 T cells into effector cyto-
toxic T cells (21–23). Studies with CD27
 
   
 
 mice revealed
impaired expansion of antigen-specific T cells in primary
and memory T cell responses to influenza virus infection
(24). Complementary to these results, increased generation
of effector-type T cells was found in B cell–specific CD70
transgenic (Tg) mice that was dependent on TCR trigger-
ing (25, 26). Here, we addressed the question whether
CD27–CD70 interactions modify quantitative and qualita-
tive aspects of the instructional program of antigen-specific
CD8
 
 
 
 T cell development. The results show that CD27
triggering enhances both the expansion and the functional
activity of antigen-specific effector T cells. As an apparent
consequence of this, CD70 Tg mice are protected from
otherwise lethal tumors.
 
Materials and Methods
 
Mice
 
C57BL/6 (wild-type), CD27
 
 
 
/
 
 
 
 CD70 Tg (25), F5 TCR Tg (27),
IFN-
 
 
 
   
 
 (28), Ly5.1 mice, and CD70 Tg mice crossed with F5
TCR Tg or IFN-
 
 
 
   
 
 mice were maintained at the animal depart-
ment of the Netherlands Cancer Institute. All mice were on a
C57BL/6 background. All mice used were 6–9 wk of age and han-
dled in accordance with institutional and national guidelines.
 
Antibodies, Tetramers, and Peptides
 
The following monoclonal antibodies were used: allophycocya-
nin-conjugated anti-CD8 (clone 53-6.7; BD Biosciences), FITC-
conjugated anti-CD43 (clone 1B11; BD Biosciences), allophyco-
cyanin-conjugated anti–IFN-
 
 
 
 (clone XMG1.2; BD Biosciences),
PE-conjugated V
 
 
 
11 TCR (clone RR3-15; BD Biosciences),
PE-conjugated mouse anti–human granzyme B (clone GB11;
CLB), and PE-conjugated mouse IgG1 isotype control (Becton
Dickinson). Rat anti–mouse CD4 (clone GK1.5) and rat anti–
mouse CD8 (clone 2.43) used in depletion experiments as well as
rat anti–mouse CD8 (clone 53-6.7) used for immunohistochemis-
try and hamster anti–mouse CD27 (clone LG.3A10) were purified
from hybridoma culture supernatant. F(ab)
 
2
 
 fragments of the
CD27 mAb were prepared and FITC labeled according to stan-
dard procedures. The influenza virus-specific H2-D
 
b
 
-NP
 
366-374
 
and H2-D
 
b
 
-PA
 
224-233
 
, and the Moloney virus–specific H2-D
 
b
 
-
GagL
 
85-93
 
 tetramers were prepared as described previously (29–
31). The nucleoprotein (NP)-derived peptide ASNENMDAM
(366–374) was produced using standard F-moc chemistry.
 
Virus Infection and Adoptive Transfers
 
Purified influenza A virus was provided by R. Consalves (National
Institute for Medical Research, London, England, UK) and grown
in the Department of Virology at Erasmus University. Mice were
anesthetized and infected intranasally with 25 HAU of influenza
virus. Detection of influenza virus in lung homogenates was done
using real-time quantitative PCR as described previously (32).
For adoptive transfers, CD8
 
 
 
 T cells were purified from
spleens of F5 TCR Tg mice and F5 TCR Tg 
 
  
 
CD70 Tg mice
by negative selection using the MACS separation system as de-
scribed previously (25). Cells were either unlabeled or labeled
with 2 
 
 
 
m carboxyfluorescein succinimidyl ester (CFSE) in PBS
at 37
 
 
 
C for 10 min and injected i.v. into Ly5.1 recipient mice.
Where indicated, recipient mice were infected with influenza vi-
rus 1 d after adoptive transfer.
 
Tumor Challenge and T Cell Depletion
 
Tumor cells used were EL4, EL4-NP, and EL4–green fluorescent
protein (GFP; reference 33). Tumor cells were maintained in
IMDM supplemented with 5% heat-inactivated FCS, 5 
 
 
 
 10
 
 
 
5
 
 M
 
 
 
-mercaptoethanol, 100 U/ml penicillin, and 100 
 
 
 
g/ml strepto-
mycin. Mice were challenged s.c. in the right flank with 10
 
6
 
 tu-
mor cells. Every 3–4 d, tumor size was measured in two dimen-
sions. Mice were killed when tumors reached diameters 
 
 
 
15 mm.
In vivo depletion of CD4
 
 
 
 and CD8
 
 
 
 T cells was accom-
plished by intraperitoneal injections with 0.6 mg of rat anti–
mouse CD4 mAb (clone GK1.5) or 0.6 mg rat anti–mouse CD8
mAb (clone 2.43), respectively, at days 
 
 
 
4, 0, 3, 7, 9, 12, and 15
in relation to tumor challenge. The absence of CD4
 
 
 
 or CD8
 
 
 
 T
cells was determined by FACS
 
®
 
 analysis with FITC-conjugated
anti-CD4 (clone MT4) and PE-conjugated anti-CD8 (clone 53–
6.7), respectively.
 
Detection of Antigen-specific Immune Responses 
and Cytotoxicity Assay
 
Flow Cytometry. 
 
At indicated time points, blood was drawn
from the tail vein, and single cell suspensions from spleen, LNs,
lungs, and tumors were obtained by mincing through cell strain-
ers. Erythrocytes in spleen and blood were lysed with ammonium
chloride solution. Cells were counted and incubated at room tem-
perature for 15 min with antibodies and tetramers. Live cells were
selected based on 2 
 
 
 
g/ml propidium iodide exclusion. Absolute
numbers of antigen-specific T cells were calculated from the fre-
quency of H-2D
 
b
 
 tetramer
 
 
 
 CD8
 
 
 
 cells and the total numbers of
cells recovered. Intracellular staining for granzyme B was per-
formed with PE-labeled mouse anti–human granzyme B and PE-
labeled mouse IgG1 (isotype control) using a Cytofix/Cytoperm
Kit (BD Biosciences) according to the manufacturer’s guidelines.
Flow cytometric analyses were performed on a FACSCalibur™
using CELLQuest™ software (Becton Dickinson). Statistical anal-
yses were performed with a two-tailed Student’s 
 
t
 
 test.
 
Intracellular Cytokine Staining. 
 
10
 
6 
 
cells/well spleen cells were
stimulated for 5 h at 37
 
 
 
C and in 5% CO
 
2
 
 conditions in flat-bot-
tom 96-well plates in 200 
 
 
 
l IMDM (Life Technologies) with 20
U/ml of recombinant human IL-2 and 1 
 
 
 
g/ml brefeldin A
(Sigma-Aldrich) in the presence or absence of 1 
 
 
 
g/ml NP
 
366-374
 
peptide. After stimulation, cells were first surface stained for
CD8, and subsequently intracellular cytokine staining was per-
formed for IFN-
 
 
 
 using a Cytofix/Cytoperm Kit (BD Bio-
sciences) according to the manufacturer’s guidelines.
 
Flow Cytometry CTL Assay. 
 
The flow cytometry CTL assay
(OncoImmunin; reference 34) was performed according to the
guidelines from the manufacturer with some modifications as de-
scribed in this paragraph. To obtain effector cells, spleens of wild-
type and CD70 Tg mice challenged with EL4-NP tumor cells
were collected at day 9 after tumor challenge, and single cell sus-
pensions were prepared by mincing through cell strainers. T cells
were purified using Thy1.2 microbeads and the MACS system
(Miltenyi Biotec). Purified T cells (
 
 
 
95%) were stained with
CD8 mAb and H-2D
 
b
 
-NP
 
366-374
 
 tetramers to define effector cell
numbers (i.e., NP
 
366-374
 
-specific CD8
 
 
 
 cells). Target cells (EL4
cells) were suspended in IMDM containing 10% FCS at 10
 
6
 
 cells/
ml, fluorescently labeled, and pulsed with 10 
 
 
 
g/ml NP
 
366-374
 
peptide for 1 h at 37
 
 
 
C and in 5% CO
 
2
 
 conditions. Target cells
were incubated with effector cells at various effector/target cell
ratios in a 96-well plate for 2.5 h at 37
 
 
 
C in a 5% CO
 
2
 
 incubator. 
Arens et al.
 
1597
 
After washing, cells were incubated with caspase substrate for 40
min, washed, and analyzed by flow cytometry.
 
Immunohistochemistry
 
CD8
 
 
 
 T cell infiltrates in tumor tissue were assessed by immuno-
histochemistry. Tumors were cut into pieces and frozen in Tis-
sueTek (Sakura Finetek) at 
 
 
 
70
 
 
 
C, and 6-
 
 
 
m cryostat sections
were prepared. These sections were applied on gelatin-coated
microscope glass slides, fixed in dehydrated acetone for 10 min,
air dried, and rehydrated with 2% newborn calf serum in PBS.
The sections were incubated for 45 min with biotinylated rat
anti–mouse CD8 mAb, washed three times with PBS, and subse-
quently incubated for 30 min with Alexa 594–conjugated strepta-
vidin (Molecular Probes). Sections were washed with PBS, and
nuclei were counterstained with Hoechst 33342 and finally cov-
erslipped with Fluorostab (ICN/Cappel). Fluorescence was ana-
lyzed using a microscope (Eclipse model E800; Nikon) con-
nected to a digital camera.
 
Online Supplemental Material
 
Fig. S1 shows the B and T cell phenotype of the CD70 Tg mice
at the time of the antigenic challenge. Splenocytes of 6-wk-old
wild-type and CD70 Tg mice were isolated and analyzed by flow
cytometry for CD70 and B220 expression (Fig. S1 A), CD27 and
Thy1.2 expression (Fig. S1 B), and CD43 (1B11) and NP
 
366-374
 
tetramer expression (Fig. S1 C, gated on CD8
 
 
 
 T cells). Online
supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20031111/DC1.
Figure 1. Increased generation of antigen-
specific CD8  T cells in CD70 Tg mice after
influenza virus infection. Wild-type and
CD70 Tg mice were infected intranasally
with influenza virus. (A) Representative
FACS® profiles of blood cells collected at
day 0 and at day 9 after infection showing
H-2Db-NP366-374 tetramer staining versus
CD8. Numbers indicate the percentages of
H-2Db-NP366-374–specific cells within the
CD8  T cell compartment. No cells were
stained with Moloney virus–specific (H-2Db-
GagL85-93) tetramers (not depicted). (B) Fre-
quency of H2-Db-NP366-374 tetramer positive
cells among CD8  T cells in blood at the
indicated days after influenza virus infection.
Data represent mean values and standard error
from 10 mice per group. Significance of dif-
ferences was determined by two-tailed Stu-
dent’s t test (*, P   0.05; **, P   0.005).
(C) Expansion and contraction of NP366-374-
specific CD8  T cells in blood was normal-
ized to the peak of the response (at day 9).
(D) Absolute numbers of NP366-374-specific
and (E) PA224-233-specific CD8  T cells in
spleens, DLNs, and lungs 9 d after infection.
Data representing the mean and standard error
from six mice per group are shown. Signifi-
cance of differences was determined by two-
tailed Student’s t test (*, P   0.05; **, P  
0.005). Both groups of mice showed no dif-
ference in kinetics of viral clearance. (F) Con-
traction of antigen-specific CD8  T cells in
the spleen was normalized to the peak of
the response (at day 9).Improved Effector CD8  T Cell Formation by CD70 Costimulation 1598
Results
Increased Antigen-specific Effector CD8  T Cell Expansion in
CD70 Tg Mice after Influenza Infection. To test the impact
of CD27 ligation on the kinetics of the immune reaction in
a physiological virus infection model, influenza virus-spe-
cific CD8  T cell responses of intranasally influenza virus–
infected wild-type and CD70 Tg mice were compared
longitudinally using MHC class I tetramers. At the peak of
the response, at day 9 after infection, influenza-specific
CD8  T cell frequencies as measured by NP366-374 tetramer
staining in peripheral blood were moderately increased in
CD70 Tg mice as compared with wild-type mice (Fig. 1, A
and B). Analyses of the ensuing time points revealed a
modest delay in contraction of the influenza-specific CD8 
T cell pool in peripheral blood of CD70 Tg mice (Fig. 1, B
and C). Finally, percentages of tetramer-binding T cells re-
maining long after viral clearance (day 27) were signifi-
cantly higher in the CD70 Tg mice than in wild-type mice
(Fig. 1 B). The kinetics and magnitude of the influenza-
specific CD8  T cells paralleled the expression of the ef-
fector cell marker 1B11 (35), recognizing the activation-
associated glycoform of CD43 on the total CD8  T cell
population (unpublished data).
At the peak of the response, the absolute numbers of
NP366-374-specific CD8  T cells in spleen and lung were
significantly increased in CD70 Tg mice as compared with
wild-type mice (Fig. 1 D). In lung/draining LNs (DLNs),
the absolute numbers of NP366-373-specific CD8  T cells
were slightly but not significantly increased in CD70 Tg
mice (Fig. 1 D). Comparable results were obtained with
tetramers loaded with the PA224-233 epitope of influenza vi-
rus (Fig. 1 E). Although no difference in contraction of the
influenza virus–specific CD8  T cell populations in lung
and DLNs was found, a modest delay in contraction of
NP366-373- and PA224-233-specific CD8  T cell populations
in the spleen was observed (Fig. 1 F). To exclude the possi-
bility that the increased numbers of antigen-specific CD8 
T cells in the CD70 Tg mice were caused by differences in
viral clearance, we determined the viral titers in the lung of
infected mice at several time points. At day 9 after infec-
tion, the viral titers were not significantly different. If any-
thing, viral titers were lower in CD70 Tg mice compared
with wild-type mice (unpublished data). At days 14 and 23
after viral infection in both groups of mice, no virus could
be detected anymore.
The aforementioned results indicate that constitutive
CD70 expression enhances the expansion of antigen-spe-
cific CD8  T cells upon influenza virus infection. These
findings might either be due to a broadening of the T cell
repertoire specific for a given influenza antigen or to in-
creased accumulation of the progeny of a similar repertoire
of T cells. To determine the effects of constitutive CD70
expression on a monoclonal antigen-specific CD8  T cell
population, we bred mice Tg for the MHC class I–restricted
TCR recognizing the influenza virus epitope NP366-374 (F5
TCR Tg; reference 27) with CD70 Tg mice. After influ-
enza infection, F5 TCR Tg   CD70 Tg mice showed in-
creased frequencies of CD8  T cells with a CD43hi effector
phenotype in peripheral blood as compared with F5 TCR
Tg mice. This started at day 2 after infection and was main-
tained until day 31 (Fig. 2 A). At the peak of the response,
at approximately day 9 after infection, frequencies as well
as absolute numbers of CD43hiCD8  effector T cells were
significantly increased in both spleen and DLNs, but not in
lung tissue of F5 TCR Tg   CD70 Tg as compared with
F5 TCR Tg mice (Fig. 2, B and C), indicating that CD70
costimulation also enhances expansion of monoclonal CD8 
T cells. This excludes the possibility that our data can be
explained by a CD70-mediated, TCR triggering–indepen-
dent polyclonal T cell activation.
To establish whether the CD70-mediated increase in an-
tigen-specific CD8  T cell responses is dependent on its
interaction with CD27, we challenged CD70 Tg mice on a
Figure 2. Increased effector CD8  T cells in NP-
specific TCR Tg   CD70 Tg mice. F5 TCR Tg and
F5 TCR Tg   CD70 Tg mice were infected intrana-
sally with influenza virus. (A) Frequency of CD43hi-
expressing CD8  T cells in blood at the indicated days
after influenza virus infection. Data represent mean values
and standard error of five mice per group. Significance
of differences was determined by two-tailed Student’s t
test (*, P   0.05; **, P   0.005). (B) Representative
FACS® profiles of spleen, lung, and DLNs collected at
day 9 after influenza virus infection showing CD43
staining on gated CD8  T cells of TCR Tg mice
(shaded histograms) and TCR Tg   CD70 Tg mice
(solid lines). Numbers indicate the percentage of
CD43hi cells within the CD8  T cell compartment.
(C) Absolute numbers of CD43hiCD8  T cells in
spleen, lung, and DLNs at day 9 after infection. Data
represent mean values and standard error of five mice
per group. Significance of differences was determined
by two-tailed Student’s t test (**, P   0.005).Arens et al. 1599
CD27-deficient background with influenza virus. The
observed increase in the numbers of splenic influenza-spe-
cific CD8  T cells in CD70 Tg mice was not found in
CD27      CD70 Tg mice (Fig. 3 A), indicating an abso-
lute requirement for CD27.
The expression of CD27 is low to undetectable in CD70
Tg and F5 TCR Tg   CD70 Tg mice at the time of TCR
triggering (Fig. 3 B and Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20031111/DC1).
Therefore, the effects observed in the CD70 Tg mice could
either be explained by constitutive triggering of CD27 via
CD70 or by CD70-induced presensitization of the T cells,
resulting in an increased responsiveness at the time of anti-
gen encounter. To determine whether CD27 is perma-
nently lost on T cells in CD70 Tg mice, or whether the
absence of CD27 cell surface expression is due to continu-
ous triggering by CD70, we analyzed CD27 expression on
T cells of F5 TCR Tg and F5 TCR Tg   CD70 Tg mice
after adoptive transfer into wild-type mice. Within 24 h af-
ter adoptive transfer, CD27 expression was found on both
adoptively transferred T cell populations (Fig. 3 B). CD27
expression was also detectable on both TCR Tg and TCR
Tg   CD70 Tg T cells after 1 d of in vitro culture in the
presence of concanavalin A (unpublished data). These data
indicate that the T cells in CD70 Tg mice continue to pro-
duce CD27, but downmodulate the molecule due to con-
tinuous interaction with CD70.
To determine whether CD27 ligation by CD70 could
have presensitized T cells, CD8  T cells of F5 TCR Tg
and F5 TCR Tg   CD70 Tg mice were labeled with
CFSE, a fluorescent dye that is diluted with each cell divi-
sion, and injected into Ly5.1 recipient mice that were in-
fected with influenza virus 1 d later. No significant differ-
ences were observed in CFSE dilution between DLN T
cells from F5 TCR Tg mice and from TCR Tg   CD70
Tg mice at day 4 after infection (Fig. 3 D, 55   21% F5
TCR Tg T cells with  6 cell cycle divisions vs. 67   18%
F5 TCR Tg   CD70 Tg T cells; n   8). In addition, no
significant differences in absolute numbers of influenza-
specific CD8  T cells between the two groups were ob-
served at days 5 and 7 after influenza infection (unpublished
data). Collectively, these data indicate that the CD70-
mediated effects on antigen-specific T cell responses can
be explained by constitutive CD27 ligation during anti-
genic challenge rather than a presensitizing effect of CD27–
CD70 interactions. Overall, triggering of CD27 augments
initial expansion, modestly delays the contraction phase,
and maintains higher numbers of CD8  T cells in the
memory stage upon influenza virus infection.
Increased Antigen-specific CD8  T Cell Expansion upon Tu-
mor Challenge. The effects of CD27 ligation in vivo on
antitumor CD8  T cell responses were analyzed using
EL4 tumor cells that express the influenza A virus–derived
NP366-374 epitope. These tumor cells induce an NP366-374-
specific CD8  T cell response and tumor rejection in nor-
mal mice (33). Subcutaneously inoculated EL4-NP tumor
cells were rejected in wild-type and CD70 Tg mice with
similar kinetics (Fig. 4 A). The percentage of NP366-374-spe-
cific CD8  T cells at the peak of the response (day 13 after
tumor challenge) and on consecutive days, was increased
Figure 3. CD70-mediated effects on antigen-specific CD8  T cell re-
sponses require CD27 stimulation during antigen encounter. (A) Wild-type,
CD27 / , CD70 Tg, and CD27 /    CD70 Tg mice were infected
intranasally with influenza virus. At day 9 after infection, spleens were
collected, and absolute numbers of NP366-374-specific CD8  T cells were
determined. (B) Reduced CD27 expression on T cells in CD70 Tg  
TCR Tg mice requires continuous triggering by CD70. Splenic CD8  T
cells from F5 TCR Tg mice and F5 TCR Tg   CD70 Tg mice were
purified and stained with mAbs specific for V 11 and CD27 (top). 1 d after
adoptive transfer of 4   106 purified CD8  T cells from F5 TCR Tg mice
and F5 TCR Tg   CD70 Tg mice into Ly5.1 mice, spleen cells were
stained with mAbs specific for CD8, CD27, and Ly5.2 (bottom). Dot plots
are gated on CD8  T cells. (C) Purified CD8  T cells from F5 TCR Tg
mice and F5 TCR Tg   CD70 Tg mice were CFSE-labeled and adop-
tively transferred into Ly5.1 recipient mice. At 1 d after transfer, mice
were infected with influenza virus. 4 d after virus infection, DLN cells
were stained with mAbs specific for CD8 and Ly5.2. Flow cytometric his-
tograms of CFSE dilution on CD8 and Ly5.2-positive cells are shown.Improved Effector CD8  T Cell Formation by CD70 Costimulation 1600
approximately two- to threefold in the blood of CD70 Tg
mice (Fig. 4 B). Similarly, the absolute number of NP366-374-
specific CD8  T cells was significantly increased in the
spleen of CD70 Tg mice and slightly increased in DLNs
(Fig. 4 C). As in influenza infection, increased percentages
of CD43hiCD8  T cells were observed in the peripheral
lymphoid organs of CD70 Tg mice (unpublished data). It is
unlikely that the B cell depletion occurring in CD70 Tg
mice (25) is involved in the observed effects on CD8  T
cell responses because B cell–deficient mice show similar
CD8  T cell responses after EL4-NP challenge (unpub-
lished data). Together, these data show that CD27 stimula-
tion augments the expansion and maintenance of the anti-
gen-specific T cell pool after tumor challenge.
Increased Acquisition of Effector Cell Properties after CD27
Ligation. It is unconfirmed whether signals transmitted via
TNF receptor family members improve effector T cell re-
sponses in a qualitative fashion (36). To assess whether
CD27 stimulation contributes to the competence of anti-
gen-specific T cells, we analyzed the acquisition of effector
cell properties of NP366-374-specific T cells directly ex vivo.
At the peak of the CD8  T cell response to EL4-NP tumor
cells, splenic NP366-374-specific CD8  T cells were analyzed
for their capacity to produce IFN-  and TNF-  after in
vitro stimulation with NP366-374 peptide. The percentage of
splenic CD8  T cells producing IFN-  after NP366-374 pep-
tide stimulation was significantly increased in CD70 Tg
mice (4.1   1.0% in wild-type vs. 7.2   1.2% in CD70 Tg
mice; n   5, P   0.05). This may in large part be explained
by the increased size of the antigen-specific CD8  T cell
compartment. Remarkably, the IFN-  production on a per
cell basis was reproducibly higher (Fig. 5 A, 316   68
mean fluorescence intensity (MFI) wild-type vs. 582   98
MFI CD70 Tg mice; n   5, P   0.05). Constitutive CD27
ligation had no effect on TNF-  production in CD8  T
cells (Fig. 5 A). The contribution of CD27–CD70 interac-
tion to the development of cytotoxic activity to NP366-374
peptide–loaded EL4 cells was examined using a recently
described flow cytometric CTL assay (34). On a per cell
basis, the ex vivo cytotoxicity of splenic NP-specific CD8 
T cells was enhanced in CD70 Tg mice as compared with
wild-type mice (Fig. 5, B and C). Furthermore, the in-
crease in cytotoxic activity in T cells of CD70 Tg mice was
associated with augmented granzyme B expression in both
CD8  T cells and NP-specific CD8  T cells in terms of in-
tensity and percentages (Fig. 5 D). As predicted, granzyme
B expression was primarily found in the CD43  effector T
cell subset. Also, after influenza infection, splenic anti-
gen-specific CD8  T cells in CD70 Tg mice had in-
creased IFN-  expression and cytotoxic activity (unpub-
lished data). Thus, apart from increasing the size of the
effector T cell pool, CD27 stimulation enhances the capac-
ity of CD8  effector T cells to produce IFN-  and to exe-
cute cytolysis of antigen-bearing target cells.
CD8  T Cell– and IFN- –dependent Tumor Regression in
CD70 Tg Mice. The aforementioned findings showed that
in the presence of a strong CD27 signal, both quantity and
quality of CD8  T cell responses improve. To evaluate the
possible benefits of this for increased immunity, the ability
of CD8  T cells to control growth of poorly immunogenic
tumors was evaluated in CD70 Tg and wild-type mice. In
view of this purpose, we examined the response to EL4 tu-
mor cells and EL4 tumor cells transduced with a retroviral
vector containing GFP and the Moloney-derived MHC
class I–restricted GagL85-93 epitope. The GagL epitope en-
coded by the Moloney retrovirus is derived from an alterna-
tive translation initiation site, and presentation of this
epitope is insufficient to allow immune control of EL4-GFP
tumors in wild-type mice (33). EL4 and EL4-GFP tumor
cells grew progressively in wild-type mice, whereas in
CD70 Tg mice, both EL4 and EL4-GFP tumors regressed
at day 9 after tumor inoculation (Fig. 6, A and B). At day 9
after tumor challenge, spleens and tumors of CD70 Tg mice
challenged with EL4-GFP contained increased percentages
of tumor-specific CD8  T cells as compared with wild-type
Figure 4. Increased generation of NP-specific CD8  T cells in CD70
Tg mice after EL4-NP tumor challenge. (A) Wild-type and CD70 Tg mice
were challenged subcutaneously with 106 EL4-NP tumor cells, and tumor
size was measured at the indicated days after tumor challenge. Data repre-
sent mean values and standard error of six mice per group. (B) Frequency of
NP366-374-specific CD8  T cells in blood of wild-type and CD70 Tg mice.
Significance of differences was determined by two-tailed Student’s t test
(*, P   0.05). (C) Absolute numbers of NP366-374-specific CD8  cells in
spleen and DLNs at day 13 after tumor challenge. Significance of differ-
ences was determined by two-tailed Student’s t test (*, P   0.05).Arens et al. 1601
mice challenged with EL4-GFP (Fig. 6 C). Furthermore,
immunohistochemistry of tumor tissue at day 9 after tumor
challenge showed that in CD70 Tg mice, the tumors con-
tained larger infiltrates of CD8  T cells (Fig. 6 D).
To analyze the contribution of the CD4  and CD8  T
cell subsets in the CD70-mediated EL4 tumor regression,
CD70 Tg mice were treated with either anti-CD4 or anti-
CD8 mAbs to deplete CD4  or CD8  T cells. As shown
in Fig. 6 E, treatment of CD70 Tg mice with mAb to
CD8, but not to CD4, prevented the rejection of tumors in
CD70 Tg mice, indicating that CD8  T cells play a key
role in the CD70-mediated tumor rejection. When EL4
cells were inoculated subcutaneously in IFN-     mice or
IFN-       CD70 Tg mice, the EL4 cells grew progres-
sively in both strains of mice, indicating a critical require-
ment for IFN-  in the CD70-mediated tumor rejection
(Fig. 6 F). Together, these results show that CD27 ligation
protects against lethal tumor challenge in a CD8  T cell–
and IFN- –dependent manner, and this protection can be
correlated to an enhanced number and efficacy of tumor-
specific effector CD8  T cells.
Discussion
In the present work, we have shown that in vivo costim-
ulation of T cells by constitutive triggering of CD27 by its
ligand CD70 results in increased numbers as well as more
competent antigen-specific CD8  T cells upon challenge
with either influenza virus or EL4-NP366-374 cells. More-
over, challenge with a lethal dose of poorly immunogenic
EL4 lymphoma cells results in a CD8 - and IFN- –depen-
dent rejection of the tumor in CD70 Tg mice, but not in
wild-type mice.
The observed CD70-mediated enhancement of antigen-
specific CD8  T cell responses is both quantitative and
qualitative. With respect to the quantitative effects, the in-
Figure 5. Increased IFN-  production
and cytotoxic activity in CD70 Tg mice.
Phenotypic analysis of splenic CD8  T cells
of wild-type and CD70 Tg mice collected
12 d after challenge with 106 EL4-NP tumor
cells. (A) Intracellular IFN-  and TNF- 
staining of NP366-374-specific CD8  T cells.
Intracellular IFN-  and TNF-  levels were
measured in spleen cells after 5 h of incubation
in the presence or absence of NP366-374 pep-
tide. The percentage and MFI of IFN-  
and TNF  cells within the CD8  gate are
indicated. Background (no peptide) was
 0.2%. (B) Cytotoxic activity of NP366-374-
specific CD8  T cells. Target cells (EL4
cells) were fluorescently labeled, pulsed
with NP366-374 peptide or unpulsed, and
subsequently cocultured with effector cells
(NP366-374-specific CD8  T cells) at differ-
ent effector to target cell ratios in which
effector populations from wild-type and
CD70 Tg mice were equalized based on the
percentage of NP-specific cells. Killing of
target cells was assessed by a flow cytometric
CTL assay detecting the induction of cas-
pase activity in target cells. Histograms are
gated on EL4 target cells, and the numbers
indicate the percentage caspase positive
cells. The solid and dotted lines represent
peptide-pulsed or unpulsed target cells, re-
spectively. (C) Measurement of cytotoxicity
as described in B with different effector to
target cell ratios. Data are displayed as mean
and standard error (n   5). (D) Ex vivo in-
tracellular granzyme B staining. CD8  T
cells and NP366-374-specific CD8  T cells
were stained for CD43 and intracellular
granzyme B. Gated CD8  and NP366-374-
specific CD8  T cells are shown. The num-
bers indicate the percentages of cells within
the designated quadrant and are representative
of five mice.Improved Effector CD8  T Cell Formation by CD70 Costimulation 1602
creased numbers of antigen-specific CD8  T cells in CD70
Tg mice after influenza virus infection and tumor challenge
presumably enhance the efficacy of the primary response.
Recently, it was shown that the contraction of the CD8 
T cell compartment occurs independently of the continu-
ous presence of antigen (8). Here, we have found that con-
stitutive CD27–CD70 interaction results in a modest delay
in contraction of influenza-specific CD8  T cells in pe-
ripheral blood and spleen (Fig. 1, C and F), indicating that
the contraction phase can be modulated by CD8  T cell
extrinsic factors (i.e., provided by members of the TNF re-
ceptor family). Because endogenous CD70 expression on
activated lymphocytes and dendritic cells is transient and
under tight control of the presence of antigen, the contri-
bution of CD27 to T cell expansion, maintenance, and
contraction will normally depend on the amount and per-
sistence of antigen. Whether the modulation by CD70
takes place at the initiation and/or throughout the different
phases of the T cell response remains to be established.
As to the qualitative aspects of in vivo ligation of CD27,
we found an increased ex vivo cytotoxic activity of antigen-
specific CD8  T cells (Fig. 5, B and C), correlating with a
higher granzyme B expression (Fig. 5 D). This finding is
consistent with previous in vitro studies (21–23), and shows
that CD27–CD70 interactions boost the cytotoxic capacity
of CD8  T cells, thereby improving outcome of viral infec-
tions and tumor challenge. Finally, the CD27-mediated in-
duction of type 1 IFN- –producing T cells (Fig. 5 A) might
also contribute to the observed enhanced immunity because
these T cells tend to migrate to the site of infection (37). Ac-
tually, we have found numerous IFN- –producing T cells
at the effector site (unpublished data) along with splenic
IFN- –producing T cells. In addition, IFN-  secreted by
antigen-specific CD8  T cells might further enhance immu-
nity by its pleiotropic effects on the immune system, includ-
ing increased presentation of peptides by MHC class I (38).
The enhanced CD8  T cell responses by constitutive
CD70 expression on B cells is most likely due to direct liga-
Figure 6. CD8  T cell– and IFN- –
dependent  tumor rejection in CD70 Tg
mice. Mice were challenged subcutaneously
with 106 EL4 or EL4-GFP tumor cells.
Tumors were measured, and mice were
killed when tumors reached diameters of
 15 mm. (A) EL4 and (B) EL4-GFP tumor
rejection in CD70 Tg mice. Tumor size of
wild-type and CD70 Tg mice was measured
at the indicated days after tumor challenge.
Data represent mean values and standard
error of eight mice per group. (C) Increased
frequencies of CD8  T cells and tumor
specific-CD8  T cells in spleen and tumors
after EL4-GFP challenge as determined us-
ing anti-CD8 mAbs and H-2Db-GagL85-93
tetramers at day 9 after tumor challenge. (D)
CD8  T cell infiltrates (red) in EL4-GFP
tumors (blue) from wild-type and CD70 Tg
mice at day 9 after tumor challenge as deter-
mined by immunohistochemistry. (E) CD8 
T cells are critically involved in EL4 tumor
rejection in CD70 Tg mice. Tumor size
was measured at the indicated days after
EL4 tumor challenge in mice treated with
either anti-CD4 or anti-CD8 mAbs. Data
represent mean values and standard error
from five mice per group. (F) IFN-  is crit-
ically involved in EL4 tumor rejection in
CD70 Tg mice. Tumor size of IFN-  / 
and IFN-  /    CD70 Tg mice was mea-
sured at the indicated days after tumor chal-
lenge. Data represent mean and standard error
from five mice per group.Arens et al. 1603
tion of CD27 on CD8  T cells rather than CD27 ligation
on CD4  T cells, thereby increasing the T helper cell activ-
ity for four reasons. First, in viral infections, the primary
CD8  T cell responses are known to be unaffected when
CD4  T cells are absent (39–41). Second, increased CD8 
T cell responses were also observed after influenza infection
on a MHC class I–restricted TCR background (Fig. 2).
Third, the EL4-NP366-374 tumor response is MHC class I re-
stricted and independent of MHC class II (33). Fourth, we
have shown here that the rejection of the EL4 tumor in
CD70 Tg mice is CD4  T cell independent (Fig. 6 E).
The costimulatory effect of CD27 is dependent on TCR
triggering (26), indicating that CD27-derived signals syner-
gize with TCR-derived signals, which may lower the T
cell activation threshold for antigenic stimulation. CD27-
derived costimulatory signals might also up-regulate antiap-
optotic molecules, thereby promoting T cell survival. In
fact, we recently found up-regulation of Bcl-xL expression
after CD27 triggering on T cells (unpublished data), which
is in line with data obtained with the CD27 relatives OX40
and 4-1BB (42, 43). These data suggest that the prolonged
duration of antigen-specific CD8  T cell responses in
CD70 Tg mice may at least in part be explained by an anti-
apoptotic effect of CD27 triggering. In addition, prolonged
survival of antigen-specific cells enables these cells to re-
ceive additional activation and differentiation signals.
Previously, it was found that absence of CD27–CD70
interaction leads to diminished antigen-specific T cell
numbers after influenza virus infection (24). Here, we have
found that constitutive CD27 ligation results in increased
influenza-specific CD8  T cells during the expansion, con-
traction, and memory phase by stimulating the progeny of
a similar repertoire of T cells. These complementary find-
ings show that CD27–CD70 interactions play a regulatory
role in T cell responses to influenza virus. There are no a
priori reasons to assume that there is not a similar role for
CD27–CD70 interactions in other antiviral responses. In
humans with latent CMV infection, the number of anti-
gen-specific CD27  CD8  T cells was found to be linearly
related to the total number of CMV-specific CD8  T cells
(44). As these CD27  cells are most likely the consequence
of interaction with CD70, this suggests a prominent role
for CD27–CD70 interaction in driving T cell expansion
during viral infections.
Our finding that constitutive CD70 expression on B cells
results in improved antitumor immunity is in line with ear-
lier studies showing that tumors transfected with CD70
have an enhanced capacity to induce antitumor immune re-
sponses (45–47). Interestingly, our data indicate that CD70
does not need to be present on the tumor itself to have its
potent effects on antitumor immunity. Thus, targeting of
CD27 might be a therapeutic tool to enhance antigen-spe-
cific T cell responses. Because we have shown that chronic
stimulation of CD27 eventually results in lethal immunode-
ficiency due to exhaustion of the naive T cell pool (26), it is
essential to regulate the amount and duration of T cell
CD27 stimulation in vivo to avoid detrimental effects.
In summary, our work shows that in vivo CD27 ligation
by constitutive CD70 expression on B cells enhances the
primary CD8  T cell response to influenza virus and tu-
mors. CD27 stimulation results in increased antigen-spe-
cific CD8  T cell numbers and in increased IFN-  pro-
duction as well as increased cytotoxicity on a per cell basis.
This suggests that CD27 stimulation by CD70, even when
presented outside the viral or tumor environment, may
prove useful as a strategy for enhancing CD8  T cell re-
sponses to viruses and tumors.
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